Profile data is unavailable for this security.
About the company
Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of complement and is the subject of a biologics license application pending before FDA for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy. Its long-acting MASP-2 inhibitor, OMS1029, is in phase I single- and multiple-ascending-dose clinical studies. OMS906, its inhibitor of MASP-3, the key activator of the alternative pathway of complement, is advancing in clinical programs for paroxysmal nocturnal hemoglobinuria and complement 3 glomerulopathy. Its lead phosphodiesterase 7 inhibitor OMS527 is in clinical development for the treatment of cocaine use disorders.
- Revenue in USD (TTM)0.00
- Net income in USD-121.24m
- Incorporated1994
- Employees202.00
- LocationOmeros Corp201 Elliott Avenue WestSEATTLE 98119United StatesUSA
- Phone+1 (206) 676-5000
- Fax+1 (206) 676-5005
- Websitehttps://www.omeros.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Evommune Inc | 3.00m | -66.26m | 752.80m | 45.00 | -- | -- | -- | 250.93 | -2.20 | -2.20 | 0.0997 | 2.85 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -2,158.80 | -- | -- | -- | 0.0086 | -- | 40.00 | -- | -100.59 | -- | -- | -- |
| Prime Medicine Inc | 4.63m | -201.14m | 763.56m | 146.00 | -- | 6.32 | -- | 164.84 | -1.38 | -1.38 | 0.031 | 0.6696 | 0.0145 | -- | -- | 31,726.03 | -62.83 | -65.25 | -71.22 | -77.08 | -- | -- | -4,342.44 | -11,586.93 | -- | -- | 0.00 | -- | 55.28 | -2.32 | -2.69 | -- | 47.96 | -- |
| Agomab Therapeutics NV | 0.00 | -66.05m | 774.91m | 62.00 | -- | -- | -- | -- | -1.36 | -1.36 | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -23.60 | 0.009 | -- | -- | -- | -306.21 | -- | -- | -- |
| BridgeBio Oncology Therapeutics Inc | 0.00 | 4.72m | 779.09m | -- | 48.80 | 1.21 | -- | -- | 0.1996 | 0.1996 | 0.00 | 8.05 | 0.00 | -- | -- | -- | 2.44 | -- | 2.45 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 18,328.62 | -- | -- | -- |
| Annexon Inc | 0.00 | -208.88m | 784.88m | 99.00 | -- | 3.87 | -- | -- | -1.39 | -1.39 | 0.00 | 1.40 | 0.00 | -- | -- | 0.00 | -68.11 | -42.65 | -76.07 | -45.54 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -2.95 | -- | -43.78 | -- |
| Compass Pathways PLC (ADR) | 0.00 | -237.32m | 788.84m | 166.00 | -- | 17.75 | -- | -- | -2.68 | -2.68 | 0.00 | 0.3916 | 0.00 | -- | -- | 0.00 | -94.37 | -45.17 | -169.95 | -49.01 | -- | -- | -- | -- | -- | -2.19 | 0.4541 | -- | -- | -- | -30.94 | -- | -- | -- |
| Kalvista Pharmaceuticals Inc | 15.12m | -210.31m | 789.03m | 270.00 | -- | 46.41 | -- | 52.19 | -3.95 | -3.95 | 0.2838 | 0.3363 | 0.0604 | -- | 1.51 | 55,992.59 | -84.00 | -49.86 | -97.02 | -54.21 | 87.95 | -- | -1,391.14 | -- | 7.21 | -82.77 | 0.9412 | -- | -- | -- | -44.85 | -- | 33.39 | -- |
| CytomX Therapeutics Inc | 113.63m | 28.02m | 814.98m | 119.00 | 11.95 | 7.39 | 27.82 | 7.17 | 0.4027 | 0.4027 | 0.9733 | 0.6506 | 0.7646 | -- | 45.63 | 954,882.40 | 18.85 | -15.58 | 40.91 | -26.48 | -- | -- | 24.66 | -50.39 | -- | -- | 0.00 | -- | 36.45 | 19.16 | 5,700.88 | -- | -38.41 | -- |
| MapLight Therapeutics Inc | 0.00 | -92.43m | 817.17m | 109.00 | -- | -- | -- | -- | -2.23 | -2.23 | 0.00 | 1.54 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -39.26 | -- | -- | -- |
| Janux Therapeutics Inc | 10.00m | -113.63m | 817.58m | 109.00 | -- | 0.8482 | -- | 81.76 | -1.83 | -1.83 | 0.1614 | 15.85 | 0.0097 | -- | -- | 91,743.12 | -11.02 | -12.49 | -11.25 | -12.85 | -- | -- | -1,136.25 | -822.69 | -- | -- | 0.00 | -- | -5.55 | -- | -64.69 | -- | -- | -- |
| Omeros Corp | 0.00 | -121.24m | 825.28m | 202.00 | -- | -- | -- | -- | -2.04 | -2.02 | 0.00 | -3.15 | 0.00 | -- | -- | 0.00 | -48.59 | -50.90 | -66.86 | -63.20 | -- | -- | -- | -- | -- | -- | 2.72 | -- | -- | -- | -4.41 | -- | -13.15 | -- |
| BIOAGE Labs Inc | 5.92m | -75.79m | 854.15m | 62.00 | -- | 2.64 | -- | 144.36 | -2.04 | -2.04 | 0.1594 | 7.74 | 0.0184 | -- | -- | 95,435.48 | -23.59 | -- | -25.31 | -- | -- | -- | -1,280.90 | -- | -- | -- | 0.0147 | -- | -- | -- | -11.36 | -- | -- | -- |
| Arvinas Inc | 262.60m | -80.80m | 854.52m | 246.00 | -- | 1.96 | -- | 3.25 | -1.22 | -1.22 | 3.70 | 6.83 | 0.2903 | -- | 78.39 | 1,067,480.00 | -8.93 | -18.57 | -11.25 | -22.95 | -- | -- | -30.77 | -141.50 | -- | -- | 0.0009 | -- | -0.3037 | 64.50 | 59.38 | -- | -21.68 | -- |
| ARS Pharmaceuticals Inc | 142.77m | -80.04m | 876.79m | 162.00 | -- | 5.94 | -- | 6.14 | -0.9012 | -0.9012 | 1.38 | 1.49 | 0.4836 | 3.56 | 7.67 | 921,109.70 | -27.11 | -14.27 | -30.61 | -14.82 | 89.40 | -- | -56.06 | -224.85 | 6.51 | -- | 0.3946 | -- | 297,063.30 | -- | 114.71 | -- | 42.45 | -- |
| Xencor Inc | 125.58m | -91.92m | 881.53m | 260.00 | -- | 1.36 | -- | 7.02 | -1.24 | -1.24 | 1.69 | 8.84 | 0.1374 | -- | 2.79 | 482,984.60 | -10.08 | -9.90 | -11.18 | -10.89 | -- | -- | -73.37 | -51.10 | -- | -- | 0.1585 | -- | 13.65 | 0.4654 | 60.48 | -- | -25.55 | -- |
Data as of Mar 04 2026. Currency figures normalised to Omeros Corp's reporting currency: US Dollar USD
29.35%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 4.58m | 6.47% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 3.50m | 4.94% |
| Ingalls & Snyder LLCas of 31 Dec 2025 | 3.45m | 4.86% |
| UBS Securities LLCas of 31 Dec 2025 | 1.86m | 2.63% |
| Stifel Nicolaus & Co., Inc. (Investment Management)as of 31 Dec 2025 | 1.81m | 2.55% |
| Geode Capital Management LLCas of 31 Dec 2025 | 1.63m | 2.30% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 1.57m | 2.22% |
| Broadfin Holdings LLCas of 31 Dec 2025 | 905.64k | 1.28% |
| D. E. Shaw & Co. LPas of 31 Dec 2025 | 755.00k | 1.07% |
| Susquehanna Financial Group LLLPas of 31 Dec 2025 | 731.11k | 1.03% |
More ▼
Data from 31 Dec 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
